semaglutide mash indication MASH - Wegovy semaglutide for MASH with fibrosis Semaglutide: A Groundbreaking Indication for Metabolic-Associated Steatohepatitis (MASH)

Wegovy The landscape of liver disease treatment has been significantly advanced by a groundbreaking new indication for semaglutide. This glucagon-like peptide-1 receptor agonist, most notably known by the brand name Wegovy (semaglutide) injection, has received accelerated FDA approval for the treatment of Metabolic-Associated Steatohepatitis (MASH), also formerly known as Non-Alcoholic Steatohepatitis (NASH). This designation marks a pivotal moment, as semaglutide is the first GLP-1 receptor agonist approved for MASH with liver fibrosis, specifically targeting noncirrhotic forms with moderate to advanced stages.

The scientific community has been keenly observing the development of therapeutic options for MASH, a progressive liver disease characterized by fat accumulation, inflammation, and cellular damage that can lead to fibrosis and cirrhosis. For years, the primary approach for managing MASH has involved lifestyle modifications, including a reduced calorie diet and increased physical activity. However, the need for pharmacologic interventions has been pressing, and the recent approval of semaglutide offers a much-needed therapeutic avenue. The Wegovy (semaglutide) injection 2Semaglutide (subcutaneous route) - Side effects & dosage.4 mg formulation is now indicated in combination with these recommended lifestyle changes.

Clinical trials, particularly the Phase 3 ESSENCE trial, have been instrumental in demonstrating the efficacy of semaglutide in patients with MASH.Semaglutide Shows Promise for MASH Resolution, Severe ... These studies have showcased that weekly semaglutide at a dose of 2.4 mg significantly improved liver histologic results. Specifically, the trial data indicated that more than half of adults with MASH receiving semaglutide achieved resolution of steatohepatitis at 72 weeks, accompanied by a reduction in liver fibrosis stage. Furthermore, semaglutide was found to significantly improve steatohepatitis and fibrosis while enhancing metabolic markers and noninvasive liver health measures.作者：MB Bansal·被引用次数：6—FDA-indicationand Practice Recommendation: The Wegovy® formulation, whose main ingredient issemaglutide, received accelerated FDA approval in August 2025 for treatingMASHwith moderate to advanced fibrosis (consistent with stages F2-F3 fibrosis), based on interim results of the phase 3 ESSENCE trial ... This translates to a tangible improvement in liver health and a potential halt or even reversal of liver damage progression.What is MASH? | Wegovy® (semaglutide) Injection 2.4 mg

The FDA's approval is based on the significant improvements observed in MASH and fibrosis in the clinical studies. It is important to note that semaglutide is approved to treat MASH with F2-F3 fibrosis at the 2.4 mg dose. This means the indication is for patients with noncirrhotic MASH with moderate to advanced liver fibrosis, excluding those with cirrhosis. The approval also specifies that continued approval may be contingent on further clinical validation. While semaglutide is not approved to treat patients with MASH cirrhosis, and its safety and efficacy are not established for this specific subgroup, ongoing research continues to explore its potential applications.

The approval of semaglutide for MASH with fibrosis signifies a major leap forward in addressing this growing public health concern作者：S Petta·2025·被引用次数：2—Semaglutideis best used as a first‐line treatment for MASH patientswith severe metabolic dysfunction, obesity, or type 2 diabetes, with .... MASH affects a substantial portion of the population, and its progressive nature poses a significant threat to liver health. The availability of a targeted therapy like semaglutide offers hope for achieving significant MASH resolution and mitigating the long-term consequences of the diseaseAASLD Applauds FDA Approval of First GLP-1 Therapy for ....

Beyond its indication for MASH, semaglutide is also established for other metabolic conditionsSemaglutide for the treatment of metabolic dysfunction- .... As a glucagon-like peptide-1 receptor agonist, semaglutide is widely recognized for its role in managing blood glucose levels, and the semaglutide injection is used to treat type 2 diabetes by improving glycemic control in conjunction with diet and exercise.

The clinical data also suggests that semaglutide is best used as a first-line treatment for MASH patients with severe metabolic dysfunction, obesity, or type 2 diabetes, underscoring its comprehensive approach to managing related health issuesPhase 3 Trial of Semaglutide in Metabolic Dysfunction– .... While semaglutide is not yet approved for all adults with MASH, its current indication for moderate to advanced fibrosis represents a critical advancement. The substance is an injectable prescription medicine that works by modulating appetite and increasing satiety, contributing to weight management, which is often a key factor in MASH progression2025年5月9日—Semaglutide shows promise in MASH treatment,achieving significant MASH resolutionand fibrosis improvement in the ESSENCE trial. Tolerability ....

The recent FDA approval positions semaglutide to potentially become the first drug of its kind available for MASH, offering a beacon of hope for patients and healthcare providers alike2025年8月19日—The Phase 3 ESSENCE trial evaluated adults withMASHand moderate to advanced liver fibrosis, showing thatsemaglutidesignificantly improved .... Further research and clinical practice guidelines, such as those being updated by the AASLD, will continue to refine the optimal use of semaglutide in this context, providing valuable guidance for practitioners. The indication for semaglutide in MASH is a testament to ongoing innovation in pharmaceutical development and a significant step towards better managing this challenging liver condition.